tbuckley/cabot-search huggingface dataset:
PTH-147 Audit of an In-Patient Teaching Hospital Gastroenterology Workload in 2012: Abstract PTH-147 Table 1
Authors: H Maxwell, C Smart, P J Hamlin
Journal: Gut (2013)

<h3>Introduction</h3> The aim of this retrospective study was to evaluate the patient demographics, route of admission, main diagnosis, duration of stay and quality of discharge summaries on the two 25 bedded gastroenterology wards at Leeds teaching hospitals NHS trust (LTHT) over a two month period. LTHT is a tertiary referral GI unit with 9 WTE consultants covering a population of 800,000. Leeds has one of six UK liver transplant units but non-transplant hepatology is covered by general gastroenterology. <h3>Methods</h3> Patients admitted over a 2 month period on the two designated gastroenterology wards were identified from ward registers of admission. Information regarding age, gender, route of admission, main diagnosis, duration of stay and quality of the discharge summary were recorded. <h3>Results</h3> 362 patients were identified (123 (55%) male, mean age of 54 (range of 17 to 96)). Routes of admission were 254 (70%) from the emergency department or surgical assessment unit, 43 (12%) day cases, 18 (5%) elective admissions, 18 (5%) transferred from other specialities, 15 (4%) from clinic, 7 (2%) from endoscopy and 7 (2%) unclear. The main diagnoses are listed in table 1. There were 13 deaths (4% mortality). 305 patients (91%) had discharge summaries of which 290 (95%) were completed on time. Patients who died or were transferred to other specialities were not included. <h3>Conclusion</h3> These data demonstrate the caseload mix admitted to a tertiary referral GI unit. 25% of admissions were for liver disease in addition to the service provided by the transplant unit. This reflects the national problem of the increasing burden of liver disease to the NHS. Understanding the case mix facilitates service development in line with the population needs and BSG recommendations such as alcohol teams, GI bleeding rotas and the IBD service standards. A significant proportion of miscellaneous admissions were for day case infusions which may be more appropriately delivered away from the acute bed base. The unit is striving for 100% timely and fully complete eDANs. <h3>Disclosure of Interest</h3> None Declared.
ROLE OF PROPHYLACTIC MAGNESIUM SUPPLEMENTATION IN PREVENTION OF POSTOPERATIVE ATRIAL FIBRILLATION IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING: A META-ANALYSIS OF 23 RANDOMIZED CONTROLLED TRIALS
Authors: Jalaj Garg, Rahul Chaudhary, Parasuram Krishnamoorthy, Neeraj Shah, Abhishek Sharma, Babak Bozorgnia
Journal: Journal of the American College of Cardiology (2016)
Abstract 849: Detection of circulating micrometastasis in pancreatic cancer patients by immunomagnetic nanoparticles combined with RT-PCR
Authors: Jiahua Zhou, Liang Hu, Zeqian Yu, Jie Zheng, Detong Yang, Michael Bouvet, Robert M. Hoffman
Journal: Cancer Research (2010)

Abstract By the time patients are diagnosed with pancreatic cancer, circulating cancer cells probably exist. Therefore, the detection of pancreatic tumor cells in the peripheral circulation could be used to diagnose early pancreatic cancer, which would otherwise not be detected by current imaging methods. The expression levels of h-TERT, CK20, CEA, and c-met were detected in a model of circulating micrometastasis in pancreatic cancer. The sensitivity and specificity of the measurements were evaluated. The expression of the above genes was subsequently measured in the circulation of pancreatic cancer patients. We compared their expression rate in pancreatic cancer patients at different stages to screen for the indicator with highest sensitivity and specificity in the detection of circulating pancreatic cancer cells. Immunomagnetic nanoparticles combined with RT-PCR enabled the detection of one tumor cell per 1×107 peripheral blood mononuclear cells. The positive expression rates of c-met, h-TERT, CK20, and CEA in the pancreatic cancer group were 80% (20/25), 100% (25/25), 84% (21/25), and 80% (20/25), respectively, while in the benign disease control group the rates were 0% (0/15), 0% (0/15), 6.77% (1/15), and 0% (0/15), respectively. There was a significant difference in the positive expression rate between the two groups (P&amp;lt;0.05). The specificity of h-TERT, CEA, and c-met was higher than that of CK20. The positive expression rate of the four genes was not related to gender, age, tumor size, CA-199 or CEA serum levels (P&amp;gt;0.05). However, the positive expression of c-met, CK20, and CE closely correlated with tumor stage (P&amp;lt;0.05). Immunomagnetic nanoparticles combined with RT-PCR were specific and sensitive for the detection of micrometastasis. The positive expression of c-met, h-TERT, CK20, and CEA in the circulation of pancreatic patients could be used as an indicator for circulating cancer cells. The detection rate of circulating cancer cells increased to 100% by the combined measurement of the four genes, suggesting the clinical utility of this approach. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 849.
Abstract 3716: Targeted therapy of high-grade gliomas using TGF-beta2 inhibitor trabedersen (AP 12009): Results of the Phase IIb study as basis for the Phase III SAPPHIRE Study
Authors: Piotr Jachimczak, Karl-Hermann Schlingensiepen, Hubert Heinrichs, Ulrich Bogdahn
Journal: Cancer Research (2010)

Abstract Background: High-grade gliomas (HGG) strongly overexpress TGF-beta 2. Trabedersen, a phosphorothioate antisense oligonucleotide is a TGF-beta 2 inhibitor administrated intratumorally using convection-enhanced delivery (CED). So far, clinical studies in HGG have included three Phase I/II studies and one randomized, active-controlled, open-label, multinational dose-finding Phase IIb study. Methods: Main objectives of the Phase IIb study were to compare response rate, survival, and safety of 2 doses of trabedersen (10 µM or 80 µM) vs. standard chemotherapy (TMZ or PCV). 145 patients with recurrent or refractory HGG (AA WHO grade III or GBM WHO grade IV) were randomized. Trabedersen was given intratumorally by convection-enhanced delivery via a single multi-hole catheter with up to 11 treatment cycles (7-d-on, 7-d-off / cycle). Results: As in the previous Phase I/II studies, treatment with trabedersen led to long-lasting remissions in patients with recurrent or refractory AA or GBM. Trabedersen showed a good tolerability and safety profile. Overall, 10 µM was superior to 80 µM trabedersen in both efficacy and safety. Overall, the highest efficacy was observed in AA patients treated with the lower dose of trabedersen. The 10 µM trabedersen group showed a consistently higher survival rate compared to 80 µM trabedersen and standard chemotherapy (at 24 months: 83.3%, 53.3% and 41.7%, respectively). Duration of response was about 3 times longer in the 10 µM trabedersen group (29.1 months) compared to the standard chemotherapy group (8.0 months). The median overall survival was higher in both trabedersen groups than in the chemotherapy control group, with a remarkable survival benefit of 10 µM trabedersen over chemotherapy of 17.4 months. In GBM patients, trabedersen was as efficacious as standard chemotherapy. Furthermore, in a prespecified subgroup (age ≤55 years, KPS &amp;gt;80%), trabedersen patients had a markedly higher 2-year survival rate compared to standard chemotherapy (40.0 vs. 13.3%). Conclusion and Outlook: Trabedersen treatment is safe and has a clear clinical benefit in HGG. A randomized, multinational and active-controlled Phase III study (SAPPHIRE) with trabedersen as monotherapy in patients with recurrent or refractory AA (WHO grade III) has started and patient enrollment is ongoing. In this pivotal study, patients are randomized either to treatment with 10 µM trabedersen or to standard chemotherapy (TMZ or BCNU). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3716.
POOLED SAFETY AND ADVERSE EVENTS IN NINE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 AND 3 CLINICAL TRIALS OF ALIROCUMAB
Authors: Peter H. Jones, Harold Bays, Umesh Chaudhari, Robert Pordy, Christelle Lorenzato, Kathryn Miller, Jennifer Robinson
Journal: Journal of the American College of Cardiology (2015)
Tl-201 Myocardial Perfusion SPECT
Authors: SURJIT S. WADHWA, ROBERT MANSBERG, VIVIAN B. FERNANDES
Journal: Clinical Nuclear Medicine (1999)

Purpose: Tl-201 myocardial perfusion SPECT is commonly used to assess myocardial perfusion and viability. Nitrate-augmented redistribution with repeated injection facilitates the detection of reversible segments compared with standard redistribution. In this study, we investigated the potential of nitrate augmentation to improve myocardial perfusion and viability assessment without repeated injection and we also compared nitrate-augmented redistribution with delayed redistribution. Methods: Eighteen patients underwent a stress-redistribution Tl-201 SPECT study. Immediately after redistribution SPECT, each patient was administered 0.6 mg glyceryl trinitrate and nitrate-augmented redistribution SPECT acquired 30 minutes later. Each patient then returned the next day and was injected with a booster dose of Tl-201 30 minutes before the delayed redistribution SPECT acquisition. For each SPECT study, the myocardium was divided into 11 segments, and perfusion to each segment was scored on a four-point scale by consensus. An overall cardiac perfusion score was derived by summing the perfusion score for each segment. Results: Reduced stress perfusion was identified in 150 segments: 23 (15.3%) had improved perfusion after redistribution; 60 (40%) segments had improved perfusion after nitrate-augmented redistribution; 52 (34.7%) segments with reduced stress perfusion had improved perfusion after delayed redistribution. The cardiac perfusion score after stress was 15.9 ± 5.5 (means ± SD). The score increased to 17.4 ± 5.4 after redistribution. The perfusion score improved to 19.7 ± 5.8 (P < 0.05 versus redistribution) after nitrate augmentation. The cardiac perfusion score, 19.2 ± 6.4, did not improve further after delayed redistribution. Conclusions: Tl-201 SPECT with nitrate-augmented redistribution is as good or better than delayed redistribution with repeated injection for myocardial perfusion and viability assessment. Tl-201 SPECT with nitrate-augmented redistribution has significant logistical and economic advantages over traditional delayed redistribution with Tl-201 repeated injection.
Abstract P2-16-01: Prospective breast cancer quality evaluation application developed for native Android tablet and web browser for improving mutltidisciplinary breast cancer care
Authors: SR Grobmyer, N Raum, V Sposato
Journal: Cancer Research (2012)

Abstract Introduction: Easy to implement, prospective and user-friendly data collection tools are needed to insure optimal breast cancer care as defined by national quality measures. Prospective quality measurement can effectively allow rapid identification of gaps in care and identification for sources of programmatic improvement in multidisciplinary care. Methods: Our group has designed a novel prospective quality assessment tool system, which consists of 3 major integrated components: 1) a web application for administration and reporting of the data, 2) a native Android tablet application for real-time data collection of breast cancer quality parameters during tumor board, and 3) a backend database where parameters are stored and reported on. Results: The web application is the primary interface for the breast cancer coordinator (BCC) to enter information for the applicable Tumorboards. Quality parameters for measurement as determined by the breast program leadership are entered into the system by the BCC on the web application. The BCC will also enter medical record numbers of patients to be presented at each tumor board in the web based system. In order to maximize work flow and reduce error, the system was designed to interface with the hospital electronic medical record for retrieval of patient demographic data based on medical record number entry. The Android tablet is the interface to the system during weekly breast cancer tumor board. The tablet application facilitates real time, prospective collection of: tumor board attendance, tumor staging, tumor type, and collection of center chosen and required breast cancer quality measures. Data collected on the android system is stored in real time a central and secure database. Real time quality data analysis and graphical display for user defined time periods is available on the web application and Android tablet. Required tumor hospital tumor registry data is also compiled in real time reports to faciliate communication with the hospital tumor registry. Conclusions: A novel real time Android based solution has been developed for real time breast cancer care quality and tumor registry information. Use of this technology greatly simplifies data collection required for participation national breast cancer accreditation organizations such as NAPBC as well as the American Joint Commission on Cancer. Its ease of implementation and use favor its widespread adoption. Efforts to quantify the impact of this unique tool on quality of performance in a multidisciplinary breast cancer program are underway. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-16-01.
Abstract 2044: Altered microRNA expression induced by tumorigenic conazoles in mouse liver
Authors: Jeffrey A. Ross, Carl F. Blackman, Sheau-Fung Thai, Zhiquan Li, Michael Kohan, Carlton P. Jones, Tao Chen
Journal: Cancer Research (2010)

Abstract Triadimefon, propiconazole, and myclobutanil are conazoles, an important class of agricultural and therapeutic fungicides. Triadimefon and propiconazole are mouse liver tumorigens, while myclobutanil is not. As part of a coordinated study to understand the molecular determinants of conazole tumorigenicity, we analyzed the microRNA expression levels in control and conazole treated mice after 90 days of administration in feed. Groups of mice were fed either control diet or diet containing 1800 p.p.m. triadimefon, 2500 p.p.m. propiconazole or 2000 p.p.m. myclobutanil. MicroRNA was isolated from livers and analyzed using Superarray whole mouse genome miRNA PCR arrays from SABioscience. Data were analyzed using the Significance Analysis of Microarrays (SAM) procedure. We identified those miRNAs whose expression was either increased or decreased relative to untreated controls with q ≤ 0.01. The tumorigenic conazoles induced many more changes in miRNA expression than the non-tumorigenic conazole. A group of 19 miRNAs was identified whose expression was significantly altered in both triadimefon and propiconazole treated animals but not in myclobutanil treated animals. All but one of the altered miRNAs were downregulated compared to controls. The greatest fold-changes in miRNA expression were observed for mmu-mir-135b and mmu-mir-684. Among the putative targets of the miRNAs altered by tumorigenic conazoles are genes involved in regulation of apoptosis and cell proliferation. This abstract does not reflect US EPA policy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2044.
Endoscopic treatment of rectal pocket syndrome
Authors: A. Amato, A. Vannelli, F. Radaelli, S. Paggi, E. Rondonotti, G. Spinzi
Journal: Endoscopy (2013)

A 70-year-old woman was admitted with rectal pain and soiling 3 years after a Longo's stapled hemorrhoidopexy [1]. Physical examination and laboratory tests were negative. Colonoscopy showed a 30-mm bulge with a 3-mm orifice in the lower rectum. Stools could be observed through the orifice ([Fig. 1]). A pelvic magnetic resonance imaging scan highlighted a stool-laden diverticulum of the mesorectal region, 35 × 20 × 25 mm in size ([Fig. 2]). An endoscopic ultrasound color-Doppler examination showed poor vascularization of the septum between the diverticulum and the rectal lumen.
Effects of Dihydrocodeine, Alcohol, and Caffeine on Breathlessness and Exercise Tolerance in Patients with Chronic Obstructive Lung Disease and Normal Blood Gases
Authors: Ashley A. Woodcock, Elizabeth R. Gross, Andrew Gellert, Smita Shah, Margaret Johnson, Duncan M. Geddes
Journal: New England Journal of Medicine (1981)

We measured breathlessness and exercise tolerance in 12 patients with chronic airways obstruction, moderate or severe breathlessness, and low or normal arterial carbon dioxide tension, after the patients received dihydrocodeine, alcohol, caffeine, or placebo (through double-blind administration). forty-five minutes after ingestion, dihydrocodeine had reduced breathlessness by 20 per cent and increased exercise tolerance by 18 per cent, with a reduction in ventilation and oxygen consumption at submaximal work loads but with no change in spirometric volumes. Oxygen also reduced breathlessness and provided additional benefit to that achieved with dihydrocodeine (at three hours after ingestion) when the two were given together: the reduction of breathlessness was 18 per cent with dihydrocodeine; 22 per cent with oxygen; and 32 per cent with dihydrocodeine plus oxygen. Alcohol increased forced vital capacity by 9 per cent, and exercise tolerance by 7 per cent. Caffeine had no deleterious effect on breathlessness or exercise tolerance, despite increasing ventilation during rest and exercise. We conclude that opiates may be valuable for the treatment of breathlessness in selected patients; further evaluation is needed, particularly of the long-term benefits and safety. (N Engl J Med. 1981; 305:1611–6.)
FRI0473 Autoantibody signatures of systemic lupus erythematosus (SLE) patients identified with a bead-based assay approach
Authors: A. Lueking, S. Vordenbäumen, P. Budde, H. Göhler, J. Schwermann, M. Gamer, K. Marquardt, A. Telaar, D. Chamrad, C. Theek, B. Ostendorf, P. Schulz-Knappe, M. Schneider
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> SLE is a chronic multisystem autoimmune disease with yet unknown etiology. One hallmark of SLE is the B cell activation and the production of various autoantibodies. Differential diagnosis involves ANA screening which may yield also positive results in many connective tissue disorders and other autoimmune diseases, and may occur in normal individuals. More specific subtypes of antinuclear antibodies include anti-Smith and anti-double stranded DNA (dsDNA) antibodies. However, anti-dsDNA antibodies are present in just 70% SLE patients leaving a certain gap in diagnosis. <h3>Objectives</h3> In this study we characterized the autoimmune signatures of SLE patients and healthy blood donors in order to identify established plus novel autoantibodies with differential abundance in serum samples of SLE patients. <h3>Methods</h3> We used 5800 human proteins to investigate the autoantibodies present in more than 110 serum samples of SLE patients as well as healthy blood donors applying bead-based arrays (Luminex). Biostatistical analysis was performed using univariate as well as multivariate statistical algorithms. <h3>Results</h3> In addition to the well-established clinical markers Ro52/SS-A (TRIM21), ribosomal P0, ribosomal P1, ribosomal P2, SS-A/Ro60 (TROVE2), SSB and SmB/B´ new biomarkers were identified showing high discriminatory p-values and promising sensitivity and specificity. Consequently, a small protein antigen panel consisting of four new markers plus six well-established clinical markers (Ro52/SS-A, Ro60/SS-A, ribosomal P0, ribosomal P1, ribosomal P2, and SmB/B´protein) has been defined. This panel results in an improved AUC when compared to the classification performance of the established markers alone. <h3>Conclusions</h3> With novel biomarkers a large proportion of dsDNA AB-negative SLE patients can be addressed. The benefit of the identified marker panel for SLE diagnosis is currently evaluated in comparative analysis of other patient cohorts of ankylosing spondylitis, progressive systemic sclerosis, and rheumatoid arthritis. <h3>Disclosure of Interest</h3> None Declared
Aluminum Neurotoxicity in Preterm Infants Receiving Intravenous-Feeding Solutions
Authors: Nicholas J. Bishop, Ruth Morley, J. Philip Day, Alan Lucas
Journal: New England Journal of Medicine (1997)

Aluminum, a contaminant of commercial intravenous-feeding solutions, is potentially neurotoxic. We investigated the effect of perinatal exposure to intravenous aluminum on the neurologic development of infants born prematurely.
OP35 * THE PPAR AGONIST PIOGLITAZONE UPREGULATES EAAT2 EXPRESSION IN HUMAN GLIOBLASTOMA CELLS
Authors: J. Ching, S. Amiridis, A. Bjorksten, T. Zheng, S. Stylli, A. Morokoff, T. O'Brien, A. H. Kaye
Journal: Neuro-Oncology (2014)

INTRODUCTION: Glioblastoma multiforme (GBM) cells release glutamate through expression of system xc−, which exchanges intracellular glutamate for extracellular cysteine. Lack of glutamate uptake through low excitatory amino acid transporter 2 (EAAT2) expression permits high extracellular glutamate levels, causing damaging excitotoxicty to surrounding parenchyma and epileptogenesis at the peritumoural edge. PPARγ agonists upregulate EAAT2 expression and prevent glutamate mediated excitotoxicity in stroke models. We investigated PPARγ agonists in GBM glutamate regulation. METHOD: Glioma cell lines U87MG and U251, and Glioma stem cells (GSCs) isolated from freshly resected tumour specimens were exposed to increasing concentrations of Pioglitazone. Effects on cell viability, protein expression and extracellular glutamate levels were evaluated with an ATP assay, Western Blotting and HPLC respectively. RESULTS: EAAT2 expression was upregulated in a dose and time dependent manner in both U87MG and U251 cells. Glutamate levels were reduced with the addition of pioglitazone, where statistical significance was reached in U251 cells at a concentration of 30 µM pioglitazone (n = 3, p < 0.05). Pioglitazone significantly reduced the cell viability of U87MG and U251 cells at concentrations of ≥ 30 µM (n = 4, p < 0.05) and 100 µM (n = 6, p < 0.05) respectively. Photomicrographs revealed morphological changes in the glioma cell lines and inability of the GSCs to form neurospheres with increasing pioglitazone concentrations. CONCLUSION: This study provides preliminary evidence of PPARγ-mediated regulation of EAAT2 expression in human glioblastoma cells and suggests a novel treatment strategy for glioma associated seizures.